X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare STRIDES PHARMA SCIENCE with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs DISHMAN PHARMA - Comparison Results

STRIDES PHARMA SCIENCE    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE DISHMAN PHARMA STRIDES PHARMA SCIENCE/
DISHMAN PHARMA
 
P/E (TTM) x 51.7 25.1 206.1% View Chart
P/BV x 1.1 3.3 33.7% View Chart
Dividend Yield % 0.4 0.7 65.0%  

Financials

 STRIDES PHARMA SCIENCE   DISHMAN PHARMA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
DISHMAN PHARMA
Mar-16
STRIDES PHARMA SCIENCE/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,147374 306.4%   
Low Rs642129 498.1%   
Sales per share (Unadj.) Rs317.2197.8 160.4%  
Earnings per share (Unadj.) Rs7.821.2 37.0%  
Cash flow per share (Unadj.) Rs25.134.7 72.2%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.20.8 28.1%  
Book value per share (Unadj.) Rs274.3179.9 152.5%  
Shares outstanding (eoy) m89.5080.69 110.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.81.3 221.6%   
Avg P/E ratio x114.011.9 960.9%  
P/CF ratio (eoy) x35.77.2 492.6%  
Price / Book Value ratio x3.31.4 233.2%  
Dividend payout %25.59.4 270.3%   
Avg Mkt Cap Rs m80,05820,306 394.3%   
No. of employees `0002.50.8 302.4%   
Total wages/salary Rs m4,3415,355 81.1%   
Avg. sales/employee Rs Th11,325.819,252.7 58.8%   
Avg. wages/employee Rs Th1,731.46,459.5 26.8%   
Avg. net profit/employee Rs Th280.12,064.1 13.6%   
INCOME DATA
Net Sales Rs m28,39415,961 177.9%  
Other income Rs m941265 354.4%   
Total revenues Rs m29,33416,226 180.8%   
Gross profit Rs m3,9654,103 96.6%  
Depreciation Rs m1,5401,091 141.2%   
Interest Rs m1,962944 207.8%   
Profit before tax Rs m1,4032,334 60.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1681 -15,272.7%   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m97624 15.6%   
Profit after tax Rs m7021,711 41.0%  
Gross profit margin %14.025.7 54.3%  
Effective tax rate %6.926.7 25.9%   
Net profit margin %2.510.7 23.1%  
BALANCE SHEET DATA
Current assets Rs m24,83611,018 225.4%   
Current liabilities Rs m18,9939,517 199.6%   
Net working cap to sales %20.69.4 218.8%  
Current ratio x1.31.2 113.0%  
Inventory Days Days71110 64.2%  
Debtors Days Days11335 325.5%  
Net fixed assets Rs m34,28916,304 210.3%   
Share capital Rs m895161 554.5%   
"Free" reserves Rs m23,65112,907 183.2%   
Net worth Rs m24,54614,516 169.1%   
Long term debt Rs m15,5134,189 370.3%   
Total assets Rs m65,43729,805 219.6%  
Interest coverage x1.73.5 49.4%   
Debt to equity ratio x0.60.3 219.0%  
Sales to assets ratio x0.40.5 81.0%   
Return on assets %4.18.9 45.7%  
Return on equity %2.911.8 24.3%  
Return on capital %6.917.5 39.3%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m15,6974,952 317.0%   
Fx outflow Rs m735697 105.5%   
Net fx Rs m14,9624,255 351.7%   
CASH FLOW
From Operations Rs m1,8712,786 67.1%  
From Investments Rs m5,826-1,529 -381.1%  
From Financial Activity Rs m-10,157-941 1,079.3%  
Net Cashflow Rs m-2,615316 -826.5%  

Share Holding

Indian Promoters % 27.7 61.4 45.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 3.7 1,021.6%  
FIIs % 8.6 12.7 67.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 22.1 117.2%  
Shareholders   56,241 46,261 121.6%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   PFIZER  ABBOTT INDIA  PANACEA BIOTECH  WYETH LTD  GSK PHARMA  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

From Urjit Patel to Shaktikanta Das; What Lies Ahead?(Podcast)

The week gone by saw Sensex plunge from 700 points to rise by over 600 points. With a volatile and eventful week, it was a challenge keeping up with the news every day.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES SHASUN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Oct 1, 2018 | Updated on Oct 1, 2018

Here's an analysis of the annual report of STRIDES SHASUN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES SHASUN LTD. Also includes updates on the valuation of STRIDES SHASUN LTD.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Dec 14, 2018 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS